
Conference Coverage
Latest News

Spectris Misses Primary End Point in Pivotal HOPE Trial for Alzheimer Disease

Orlando Forum Weighs Dual Antiplatelet Therapy Duration After Stroke

Navigating a New Era of Neuromuscular Drug Development and Care at MDA 2027

Trial Enrollment Complete for Pivotal Phase 2/3 Study of CB03-154 in ALS

Roche Launches Phase 2 TARBELA-AD Trial of NLRP3 Inhibitor in Alzheimer Disease

Shorts










Continuing Medical Education
All News

The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.

Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.

Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is National Epilepsy Awareness Month!

Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.

As diabetes drugs are tested for repurposing in Alzheimer disease, the negative phase 3 EVOKE and EVOKE+ results for oral semaglutide have moved attention toward prevention and earlier, combination-based approaches.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.

At a NeurologyLive Clinical Forum in Philadelphia, Pennsylvania, Chafic Karam, MD, chief of neuromuscular medicine at Penn Medicine, discussed treatment sequencing in myasthenia gravis.

The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.

At a NeurologyLive Clinical Forum, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how patients with NF1-associated plexiform neurofibromas get recognized, referred, and treated.





























